SCNI vs NVAX vs DYAI vs IBIO vs VXRT

For growth investors, Vaxart, Inc.

(VXRT) is the stronger pick with 726. 7% revenue growth year-over-year, versus 20. 6% for Dyadic International, Inc. (DYAI). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Novavax, Inc. (NVAX) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Vaxart, Inc. at 10. 6x.

Over the past 5 years, Dyadic International, Inc.

(DYAI) delivered a total return of -82. 1%, compared to -99. 8% for Scinai Immunotherapeutics Ltd. (SCNI). Over 10 years, the gap is even starker: DYAI returned -56. 4% versus IBIO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vaxart, Inc.

(VXRT) is the lower-risk stock at 0. 77β versus Novavax, Inc. 's 2. 11β — meaning NVAX is approximately 175% more volatile than VXRT relative to the S&P 500. On balance sheet safety, Vaxart, Inc. (VXRT) carries a lower debt/equity ratio of 10% versus 2% for Dyadic International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vaxart, Inc.

(VXRT) is pulling ahead at 726. 7% versus 20. 6% for Dyadic International, Inc. (DYAI). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -160. 0% for Scinai Immunotherapeutics Ltd.. Over a 3-year CAGR, VXRT leads at 1204% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -45. 9% for iBio, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -46. 5% for IBIO. At the gross margin level — before operating expenses — IBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Vaxart, Inc.

(VXRT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). iBio, Inc. (IBIO) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VXRT: -95. 8%, IBIO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.